Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis.

Abstract

OBJECTIVE:

To report a case of anti-glomerular basement membrane disease (anti-GBM disease) during alemtuzumab treatment of a relapsing-remitting multiple sclerosis (RRMS) patient.

DESIGN:

Case report.

SETTING:

Outpatient neurology research protocol.

PATIENT:

A 35-year-old white female receiving alemtuzumab for RRMS in a clinical research protocol developed symptoms leading to diagnosis of anti-GBM disease.

MAIN OUTCOME MEASURE:

Patient response to the treatment of anti-GBM disease and RRMS.

RESULTS:

Early identification and treatment of anti-GBM disease resolved clinical symptoms and preserved renal function. Alemtuzumab treatment of RRMS resolved initial MS symptoms and appears to have controlled active disease to date.

CONCLUSION:

Close monitoring for potential side effects of alemtuzumab treatment in RRMS resulted in a positive outcome when anti-GBM disease was recognized and treated early.

• Authors: David Meyer, Alasdair Coles, Pedro Oyuela, Annie Purvis, David H Margolin
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 2 Issue 1 Pg. 60-3 (Jan 2013) ISSN: 2211-0348 [Print] Netherlands
• PMID: 25877456 (Publication Type: Journal Article)
• Copyright: Copyright © 2012 Elsevier B.V. All rights reserved.